GURUFOCUS.COM » STOCK LIST » Europe » Germany » HAM » Biogen Inc (HAM:IDP) » Definitions » Cyclically Adjusted Price-to-FCF
Switch to:

Biogen (HAM:IDP) Cyclically Adjusted Price-to-FCF

: 10.73 (As of Today)
View and export this data going back to 2001. Start your Free Trial

As of today (2024-02-24), Biogen's current share price is €205.60. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was €19.17. Biogen's Cyclically Adjusted Price-to-FCF for today is 10.73.

The historical rank and industry rank for Biogen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

HAM:IDP' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 10.18   Med: 33.59   Max: 107.99
Current: 10.55

During the past years, Biogen's highest Cyclically Adjusted Price-to-FCF was 107.99. The lowest was 10.18. And the median was 33.59.

HAM:IDP's Cyclically Adjusted Price-to-FCF is ranked better than
88.22% of 314 companies
in the Drug Manufacturers industry
Industry Median: 32.065 vs HAM:IDP: 10.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's adjusted free cash flow per share data for the three months ended in Dec. 2023 was €-0.331. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €19.17 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biogen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.82 15.94 13.36 14.55 12.23

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.55 14.23 13.25 11.84 12.23

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted Price-to-FCF Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.



Biogen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biogen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=205.60/19.17
=10.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.331/129.4194*129.4194
=-0.331

Current CPI (Dec. 2023) = 129.4194.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.153 99.695 0.199
201406 2.873 100.560 3.698
201409 2.788 100.428 3.593
201412 2.736 99.070 3.574
201503 2.491 99.621 3.236
201506 3.468 100.684 4.458
201509 2.528 100.392 3.259
201512 4.361 99.792 5.656
201603 3.523 100.470 4.538
201606 3.610 101.688 4.594
201609 2.886 101.861 3.667
201612 6.110 101.863 7.763
201703 -3.594 102.862 -4.522
201706 3.550 103.349 4.446
201709 5.344 104.136 6.642
201712 4.871 104.011 6.061
201803 4.798 105.290 5.898
201806 3.446 106.317 4.195
201809 6.559 106.507 7.970
201812 7.330 105.998 8.950
201903 5.986 107.251 7.223
201906 8.260 108.070 9.892
201909 7.911 108.329 9.451
201912 8.564 108.420 10.223
202003 6.303 108.902 7.491
202006 10.174 108.767 12.106
202009 5.925 109.815 6.983
202012 -2.497 109.897 -2.941
202103 3.731 111.754 4.321
202106 6.389 114.631 7.213
202109 4.252 115.734 4.755
202112 4.619 117.630 5.082
202203 0.639 121.301 0.682
202206 4.515 125.017 4.674
202209 4.198 125.227 4.339
202212 -1.704 125.222 -1.761
202303 2.468 127.348 2.508
202306 2.537 128.729 2.551
202309 3.267 129.860 3.256
202312 -0.331 129.419 -0.331

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (HAM:IDP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biogen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines